Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus–Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi

We prospectively treated patients with hepatitis C virus (HCV)–associated indolent lymphomas with genotype-appropriate direct-acting antivirals (DAAs) with the aim to evaluate virologic and hematologic outcomes. No prospective studies in this setting have been published so far. METHODS: FIL_BArT is...

Descripción completa

Detalles Bibliográficos
Autores principales: Merli, Michele, Rattotti, Sara, Spina, Michele, Re, Francesca, Motta, Marina, Piazza, Francesco, Orsucci, Lorella, Ferreri, Andrés J.M., Perbellini, Omar, Dodero, Anna, Vallisa, Daniele, Pulsoni, Alessandro, Santoro, Armando, Sacchi, Paolo, Zuccaro, Valentina, Chimienti, Emanuela, Russo, Filomena, Visco, Carlo, Zignego, Anna Linda, Marcheselli, Luigi, Passamonti, Francesco, Luminari, Stefano, Paulli, Marco, Bruno, Raffaele, Arcaini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746784/
https://www.ncbi.nlm.nih.gov/pubmed/35714311
http://dx.doi.org/10.1200/JCO.22.00668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746784/
https://www.ncbi.nlm.nih.gov/pubmed/35714311
http://dx.doi.org/10.1200/JCO.22.00668

Ejemplares similares